Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shen zhi ling oral liquid
- Development stage
- Phase 4
- Lead developer
- Shanghai University of Traditional Chinese Medicine
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Shen zhi ling oral liquid (also known as Shenzhiling oral liquid or Shen-Zhi-Ling oral liquid) is a traditional Chinese medicine (TCM) compound approved by the China Food and Drug Administration (CFDA) for the treatment of mild-to-moderate Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI). Developed by the Shanghai Geriatric Institute of Chinese Medicine at Shanghai University of Traditional Chinese Medicine and manufactured by Shandong Wohua Pharmaceutical, the formulation is composed of ten Chinese herbs: Codonopsis pilosula, Cassia Twig, Paeonia lactiflora, honey-fried Licorice root, Poria cocos, Rhizoma Zingiberis, Radix Polygalae, Acorus tatarinowii, Ossa Draconis, and Concha Ostreae. It is designed to nourish the heart and spleen, benefit qi, warm yang, resolve phlegm, and calm the mind. Preclinical and clinical studies suggest that Shen zhi ling oral liquid exerts neuroprotective effects, protects the myelin sheath, and ameliorates cerebral glucose metabolism disorders, potentially through the PI3K/Akt-mTOR pathway.
- Brand names
- Shenzhiling参枝苓
- Other names
- Shen-Zhi-LingShen-Zhi-Ling oral liquidShenzhiling KoufuyeShenzhiling oral liquid参志苓口服液参枝苓口服液参桂健脑口服液调心方
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)EGFR (Epidermal growth factor receptor)GSK3 (Glycogen synthase kinase 3 beta)HMOX1 (Heme oxygenase 1)HSP90AA1 (Heat shock protein HSP90-alpha)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)INSR (Insulin receptor)MAPK3 (Mitogen-activated protein kinase 1)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)STAT3 (Signal Transducer and Activator of Transcription 3)TP53 (Cellular Tumor Antigen p53 R175H)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on Shen zhi ling oral liquid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shen zhi ling oral liquid.